{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:26:42Z","timestamp":1792805202576,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,29]],"date-time":"2023-01-29T00:00:00Z","timestamp":1674950400000},"content-version":"am","delay-in-days":334,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF2020R1A2C2011959"],"award-info":[{"award-number":["NRF2020R1A2C2011959"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HI19C1332000020"],"award-info":[{"award-number":["HI19C1332000020"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008005","name":"Yonsei University College of Medicine","doi-asserted-by":"publisher","award":["6-2017-0105"],"award-info":[{"award-number":["6-2017-0105"]}],"id":[{"id":"10.13039\/501100008005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21 CA241918"],"award-info":[{"award-number":["R21 CA241918"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01 CA261669"],"award-info":[{"award-number":["P01 CA261669"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.radonc.2022.01.007","type":"journal-article","created":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T16:27:42Z","timestamp":1642091262000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"special_numbering":"C","title":["Lymphocyte dynamics during and after chemo-radiation correlate to dose and outcome in stage III NSCLC patients undergoing maintenance immunotherapy"],"prefix":"10.1016","volume":"168","author":[{"given":"Yeona","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yejin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Chamseddine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Hee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Ryun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ik Jae","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Hee","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Chul","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang Geol","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seungryong","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Sung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong In","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Grassberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2022.01.007_b0005","first-page":"103","article-title":"New targeted treatments for non-small-cell lung cancer - role of nivolumab","volume":"10","author":"Zago","year":"2016","journal-title":"Biologics"},{"key":"10.1016\/j.radonc.2022.01.007_b0010","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2217\/imt.14.9","article-title":"Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy","volume":"6","author":"Reiss","year":"2014","journal-title":"Immunotherapy"},{"key":"10.1016\/j.radonc.2022.01.007_b0015","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1634\/theoncologist.2014-0422","article-title":"The evolving role of immune checkpoint inhibitors in cancer treatment","volume":"20","author":"Pennock","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.radonc.2022.01.007_b0020","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1038\/bjc.2014.348","article-title":"Immune modulation for cancer therapy","volume":"111","author":"Naidoo","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.radonc.2022.01.007_b0025","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12916-017-0819-3","article-title":"Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?","volume":"15","author":"Remon","year":"2017","journal-title":"BMC Med"},{"key":"10.1016\/j.radonc.2022.01.007_b0030","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2022.01.007_b0035","doi-asserted-by":"crossref","first-page":"S1032","DOI":"10.21037\/jtd.2018.04.61","article-title":"Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer","volume":"10","author":"Tomasini","year":"2018","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.radonc.2022.01.007_b0040","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2022.01.007_b0045","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2217\/imt-2016-0150","article-title":"PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data","volume":"9","author":"Aguiar","year":"2017","journal-title":"Immunotherapy"},{"key":"10.1016\/j.radonc.2022.01.007_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106214","article-title":"Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1\/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis","volume":"80","author":"Zhang","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.radonc.2022.01.007_b0055","doi-asserted-by":"crossref","unstructured":"Egami, Saeka et al. Absolute lymphocyte count predicts immune-related adverse events in patients with non-small-cell lung cancer treated with nivolumab monotherapy: A multicenter retrospective study. Front Oncol 2021;11:618570.","DOI":"10.3389\/fonc.2021.618570"},{"key":"10.1016\/j.radonc.2022.01.007_b0060","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/jnci\/dju124","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis","volume":"106","author":"Templeton","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.radonc.2022.01.007_b0065","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.ijrobp.2019.08.047","article-title":"Impact of treatment-related lymphopenia on immunotherapy for advanced non-small cell lung cancer","volume":"105","author":"Cho","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2022.01.007_b0070","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/jnci\/djs629","article-title":"Combining radiotherapy and cancer immunotherapy: a paradigm shift","volume":"105","author":"Formenti","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.radonc.2022.01.007_b0075","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.semradonc.2014.07.005","article-title":"Radiotherapy and immunogenic cell death","volume":"25","author":"Golden","year":"2015","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.radonc.2022.01.007_b0080","doi-asserted-by":"crossref","first-page":"224","DOI":"10.2307\/3577549","article-title":"Radiosensitivity of CD4 or CD8 positive human T-lymphocytes by an in vitro colony formation assay","volume":"123","author":"Nakamura","year":"1990","journal-title":"Radiat Res"},{"key":"10.1016\/j.radonc.2022.01.007_b0085","unstructured":"Marciscano AE, et al. Elective nodal irradiation attenuates the combinatorial efficacy of stereotactic radiation therapy and immunotherapy. Clin Cancer Res. 2018;3427;2017."},{"key":"10.1016\/j.radonc.2022.01.007_b0090","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3109\/07357907.2013.767342","article-title":"Treatment-related lymphopenia in patients with stage III non-small-cell lung cancer","volume":"31","author":"Campian","year":"2013","journal-title":"Cancer Invest"},{"key":"10.1016\/j.radonc.2022.01.007_b0095","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.ijrobp.2014.04.025","article-title":"Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes","volume":"89","author":"Tang","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2022.01.007_b0100","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.semradonc.2019.12.003","article-title":"Lymphocyte-sparing radiotherapy: the rationale for protecting lymphocyte-rich organs when combining radiotherapy with immunotherapy","volume":"30","author":"Lambin","year":"2020","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.radonc.2022.01.007_b0105","doi-asserted-by":"crossref","unstructured":"Khaled M, Sarraf MRCS, et al. Neutrophil\/lymphocyte radio and its association with survival after complete resection in non-small cell lung cancer, J Thorac Cardiovasc Surg. 137;425\u2013428.","DOI":"10.1016\/j.jtcvs.2008.05.046"},{"key":"10.1016\/j.radonc.2022.01.007_b0110","doi-asserted-by":"crossref","unstructured":"Na Z, et al. Predictive value of neutrophil-lymphocyte radio and platelet-lymphocyte radio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis, Intern Immunopharm. 85; 106677.","DOI":"10.1016\/j.intimp.2020.106677"},{"key":"10.1016\/j.radonc.2022.01.007_b0115","article-title":"Radiation-induced lymphopenia during chemoradiation therapy for non-small cell lung cancer is linked with age, lung V5, and XRCC1 rs25487 genotype in lymphocytes","author":"Xie","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2022.01.007_b0120","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ijrobp.2016.10.046","article-title":"Does unintentional splenic radiation predict outcomes after pancreatic cancer radiation therapy?","volume":"97","author":"Chadha","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2022.01.007_b0125","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/j.jtho.2020.06.008","article-title":"Radiotherapy-related lymphopenia affects overall survival in patients with lung cancer","volume":"15","author":"Abravan","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2022.01.007_b0130","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ijrobp.2015.11.026","article-title":"Lymphocyte-sparing effect of stereotactic body radiation therapy in patients with unresectable pancreatic cancer","volume":"94","author":"Wild","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2022.01.007_b0135","first-page":"1","article-title":"Radiotherapy planning parameters correlate with changes in the peripheral immune status of patients undergoing curative radiotherapy for localized prostate cancer","author":"Hoffmann","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.radonc.2022.01.007_b0140","article-title":"Proton therapy reduces the likelihood of high-grade radiation\u2013induced lymphopenia in glioblastoma patients: phase II randomized study of protons vs photons","author":"Mohan","year":"2020","journal-title":"Neuro-oncology"},{"key":"10.1016\/j.radonc.2022.01.007_b0145","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.semradonc.2019.12.003","article-title":"Lymphocyte-sparing radiotherapy: the rationale for protecting lymphocyte-rich organs when combining radiotherapy with immunotherapy","volume":"30","author":"Lambin","year":"2020","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.radonc.2022.01.007_b0150","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.lungcan.2021.01.022","article-title":"Association of severe lymphopenia and disease progression in unresectable locally advanced non-small cell lung cancer treated with definitive chemoradiation and immunotherapy","volume":"154","author":"Friedes","year":"2021","journal-title":"Lung Cancer."},{"key":"10.1016\/j.radonc.2022.01.007_b0155","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ejmp.2019.12.013","article-title":"Voxel-based analysis in radiation oncology: A methodological cookbook","volume":"69","author":"Palma","year":"2020","journal-title":"Phys Med"},{"key":"10.1016\/j.radonc.2022.01.007_b0160","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6560\/ab2e16","article-title":"Spatial signature of dose patterns associated with acute radiation-induced lung damage in lung cancer patients treated with stereotactic body radiation therapy","volume":"64","author":"Palma","year":"2019","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.radonc.2022.01.007_b0165","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.ijrobp.2014.04.025","article-title":"Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes","volume":"89","author":"Tang","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2022.01.007_b0170","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3109\/07357907.2012.762780","article-title":"The etiology of treatment-related lymphopenia in patients with malignant gliomas: modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells","volume":"31","author":"Yovino","year":"2013","journal-title":"Cancer Invest"},{"key":"10.1016\/j.radonc.2022.01.007_b0175","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ijrobp.2018.01.094","article-title":"Abscopal effects with hypofractionated schedules extending into the effector phase of the tumor-specific T-cell response","volume":"101","author":"Zhang","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2022.01.007_b0180","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13014-017-0824-x","article-title":"Radiation-related lymphopenia is associated with spleen irradiation dose during radiotherapy in patients with hepatocellular carcinoma","volume":"12","author":"Liu","year":"2017","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2022.01.007_b0185","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.thorsurg.2018.12.001","article-title":"The role of the thymus in the immune response","volume":"29","author":"Thapa","year":"2019","journal-title":"Thorac Surg Clin"},{"key":"10.1016\/j.radonc.2022.01.007_b0190","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s10522-006-9061-7","article-title":"Thymic output, ageing and zinc","volume":"7","author":"Mitchell","year":"2006","journal-title":"Biogerontology"},{"key":"10.1016\/j.radonc.2022.01.007_b0195","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.4049\/jimmunol.1800716","article-title":"Human lymph nodes maintain TCF-1hi memory T cells with high functional potential and clonal diversity throughout life","volume":"201","author":"Miron","year":"2018","journal-title":"J Immunol"},{"key":"10.1016\/j.radonc.2022.01.007_b0200","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.radonc.2020.07.025","article-title":"A tumor-immune interaction model for hepatocellular carcinoma based on measured lymphocyte counts in patients undergoing radiotherapy","volume":"151","author":"Sung","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2022.01.007_b0205","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s00262-016-1931-5","article-title":"Prognostic significance of the lymphocyte-to-monocyte ratio and the tumor-infiltrating lymphocyte to tumor-associated macrophage ratio in patients with stage T3N0M0 esophageal squamous cell carcinoma","volume":"66","author":"Zhu","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.radonc.2022.01.007_b0210","first-page":"468","article-title":"Correlations between tumor-infiltrating and circulating lymphocyte subpopulations in advanced renal cancer patients treated with nivolumab","volume":"90","author":"Bersanelli","year":"2019","journal-title":"Acta Biomed"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814022000111?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814022000111?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:20:26Z","timestamp":1777504826000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814022000111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":42,"alternative-id":["S0167814022000111"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2022.01.007","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lymphocyte dynamics during and after chemo-radiation correlate to dose and outcome in stage III NSCLC patients undergoing maintenance immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2022.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}